GOG-0265

October 26, 2016

Advaxis’ Experimental Vaccine Increases Cervical Cancer 1-Year Survival Rates by 50% in Clinical Trial

News

Patients with persistent or recurrent metastatic carcinoma of the cervix (PRmCC) may strongly benefit from treatment with Advaxis‘ experimental vaccine axalimogene filolisbac (AXAL), according to preliminary data from the second ... Read more

September 1, 2015September 1, 2015

Advaxis Announces Phase 2 Study Results of Promising Vaccine Against HPV-Associated Cervical Cancer

News

Advaxis, Inc. recently announced in a press release that results from the first stage of its ongoing Phase II clinical trial (GOG-0265) investigating the company’s axalimogene filolisbac (ADXS-HPV) technology in the treatment of patients ... Read more